AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18227236 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidized coverage at $100 per month
Number of subjects: 0
Study 18227236 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 17136295 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 17136295 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 0
Study 15508781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumefantrine
Number of subjects: 21
Study 15508781 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 21
Study 10761179 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence condition
Number of subjects: 43
Study 10761179 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced condition
Number of subjects: 43
Study 9552823 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnets
Number of subjects: 36
Study 9552823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 36
Study 9552823 — intervention group
Group type: COMPARATOR
Intervention: Straight bars (reference group)
Number of subjects: 36
Study 8418171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal microsporidiosis (Enterocytozoon bieneusi)
Number of subjects: 18
Study 8418171 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with intestinal microsporidiosis
Number of subjects: 18
Study 3745702 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling electrode catheter
Number of subjects: 24
Study 28829958 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session brief family-based intervention (BFBI)
Number of subjects: 64
Study 28829958 — intervention group
Group type: COMPARATOR
Intervention: Relaxation exercises (RE)
Number of subjects: 64
Study 26694878 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 26694878 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 24001291 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 145
Study 24001291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment predictors
Number of subjects: 145
Study 24001291 — intervention group
Group type: EXPERIMENTAL
Intervention: In-treatment predictors
Number of subjects: 145
Study 22115993 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 444
Study 22115993 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-diabetic patients)
Number of subjects: 444
Study 20687121 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200mg/day
Number of subjects: 17
Study 20687121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18211998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen 40 mg kg(‐1)
Number of subjects: 50
Study 18211998 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acetaminophen 15 mg kg(‐1)
Number of subjects: 50
Study 15864237 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS trial
Number of subjects: 31500
Study 15864237 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF trial
Number of subjects: 31500
Study 15864237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trials
Number of subjects: 31500
Study 12757988 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (2-4 mg/day)
Number of subjects: 112
Study 12757988 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1500-2500 mg/day)
Number of subjects: 112
Study 12757988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 112
Study 12757988 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 112
Study 10490724 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (G‐CSF) administered subcutaneously at a dose of 5 microg/kg body weight/day from day +5 after PBSC infusion
Number of subjects: 62
Study 10490724 — intervention group
Group type: COMPARATOR
Intervention: No cytokines (control group)
Number of subjects: 62
Study 10490724 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (G‐CSF)
Number of subjects: 62
Study 8936390 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia, schizophreniform disorder, and affective disorder
Number of subjects: 394
Study 8936390 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives of patients
Number of subjects: 394
Study 8936390 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 394
Study 1770184 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychostimulants (two doses)
Number of subjects: 9
Study 6792958 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal feeding of elemental diet (ED)
Number of subjects: 34
Study 6792958 — intervention group
Group type: COMPARATOR
Intervention: Isotonic intravenous infusions of dextrose (IV)
Number of subjects: 34
Study 31984655 — intervention group
Group type: EXPERIMENTAL
Intervention: eluxadoline 100 mg twice daily
Number of subjects: 1615
Study 31984655 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1615
Study 30727840 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 125
Study 30727840 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 125
Study 30727840 — intervention group
Group type: EXPERIMENTAL
Intervention: Union of baseline ischemic core and follow-up Tmax >6s perfusion volume
Number of subjects: 125
Study 28061783 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring with case sheets/checklists
Number of subjects: 295
Study 28061783 — intervention group
Group type: COMPARATOR
Intervention: Case sheets only (Control)
Number of subjects: 295
Study 25057916 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical technique for whistler deformity repair
Number of subjects: 38
Study 25057916 — intervention group
Group type: COMPARATOR
Intervention: Control group (preoperatory measurements)
Number of subjects: 38
Study 23169470 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (2 capsules daily, 480 mg containing 1.2 mg of S-allylcysteine)
Number of subjects: 79
Study 23169470 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (4 capsules daily, 960 mg containing 2.4 mg of S-allylcysteine)
Number of subjects: 79
Study 23169470 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (1 capsule daily, 240 mg containing 0.6 mg of S-allylcysteine)
Number of subjects: 79
Study 23169470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 21215788 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine MMP-inhibitor
Number of subjects: 0
Study 21215788 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic remineralisation
Number of subjects: 0
Study 21215788 — intervention group
Group type: COMPARATOR
Intervention: No chlorhexidine (control)
Number of subjects: 0
Study 18443967 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized face-specific training protocol
Number of subjects: 10
Study 18443967 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 10
Study 17003731 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) responses from the facial nerve in experienced implant users (Nucleus 24)
Number of subjects: 165
Study 17003731 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative EABR recordings
Number of subjects: 165
Study 12706515 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic assessment for panic disorder and acute adjustment disorder with anxiety
Number of subjects: 764
Study 12706515 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of assessment for phobia
Number of subjects: 764
Study 12706515 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous history of an anxiety disorder
Number of subjects: 764
Study 10938684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic agent (n = 43)
Number of subjects: 72
Study 10938684 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant agent (n = 4)
Number of subjects: 72
Study 10938684 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprotective drugs (n = 25)
Number of subjects: 72
Study 10938684 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment expectations
Number of subjects: 72
Study 10938684 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent process
Number of subjects: 72
Study 8653992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TPGS (2.6 IU/kg) with cyclosporine (10mg/kg)
Number of subjects: 10
Study 8653992 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclosporine (10mg/kg) without TPGS
Number of subjects: 10
Study 1306665 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin, 1 mg/kg per dose, three times a day for 7 days
Number of subjects: 30
Study 1306665 — intervention group
Group type: COMPARATOR
Intervention: Oral chloramphenicol, 30 mg/kg per day, in four divided doses for 7 days
Number of subjects: 30
Study 1306665 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin, 1 mg/kg per dose, three times a day for 7 days (after chloramphenicol)
Number of subjects: 30
Study 1306665 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment
Number of subjects: 30
Study 6391137 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquarium contemplation
Number of subjects: 42
Study 6391137 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquarium contemplation with hypnosis
Number of subjects: 42
Study 6391137 — intervention group
Group type: EXPERIMENTAL
Intervention: Poster contemplation with hypnotic induction
Number of subjects: 42
Study 6391137 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemplation of a poster
Number of subjects: 42
Study 6391137 — intervention group
Group type: COMPARATOR
Intervention: Non intervention control
Number of subjects: 42
Study 30020461 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 0
Study 30020461 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 30020461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination detemir plus liraglutide
Number of subjects: 0
Study 30020461 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 28805669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with antioxidant supplementation (Group B)
Number of subjects: 50
Study 28805669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet alone (Group A)
Number of subjects: 50
Study 28805669 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group C)
Number of subjects: 50
Study 26630353 — intervention group
Group type: EXPERIMENTAL
Intervention: s-DRY (dry swabs)
Number of subjects: 130
Study 26630353 — intervention group
Group type: EXPERIMENTAL
Intervention: s-FTA (FTA cartridge)
Number of subjects: 130
Study 26630353 — intervention group
Group type: EXPERIMENTAL
Intervention: Dr-WET (liquid-based medium)
Number of subjects: 130
Study 23163410 — intervention group
Group type: EXPERIMENTAL
Intervention: High relatedness proportion condition
Number of subjects: 0
Study 23163410 — intervention group
Group type: COMPARATOR
Intervention: Low relatedness proportion condition
Number of subjects: 0
Study 22003975 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Insomnia Severity Index (ISI)
Number of subjects: 43
Study 22003975 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil Insomnia Severity Index (ISI)
Number of subjects: 43
Study 22003975 — intervention group
Group type: COMPARATOR
Intervention: Participants not receiving the parent study intervention
Number of subjects: 43
Study 18692358 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioguided occult lesion localization (ROLL) with intra-tumoral injection of Tc99m-labelled macro-aggregate albumin
Number of subjects: 100
Study 18692358 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous sentinel node biopsy with Tc99m-labelled nanocolloids via periareolar-subdermal injection
Number of subjects: 100
Study 18692358 — intervention group
Group type: EXPERIMENTAL
Intervention: ROLL and sentinel node biopsy combined
Number of subjects: 100
Study 18692358 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical excision for invasive ductal cancer
Number of subjects: 100
Study 18692358 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical excision for DCIS
Number of subjects: 100
Study 16864466 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic case management
Number of subjects: 90
Study 16864466 — intervention group
Group type: COMPARATOR
Intervention: No case management (Control)
Number of subjects: 90
Study 12877899 — intervention group
Group type: EXPERIMENTAL
Intervention: MATISSE endotoxin adsorption system
Number of subjects: 145
Study 11204259 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily)
Number of subjects: 15
Study 11204259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9197878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol implantation
Number of subjects: 12
Study 1416323 — intervention group
Group type: EXPERIMENTAL
Intervention: 857 mg/kg sodium polystyrene sulfonate in 4 mL water/g sodium polystyrene sulfonate (experimental)
Number of subjects: 6
Study 1416323 — intervention group
Group type: COMPARATOR
Intervention: Water without sodium polystyrene sulfonate (control)
Number of subjects: 6
Study 1416323 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 6
Study 2863754 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 120
Study 2863754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29747310 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Number of subjects: 0
Study 29747310 — intervention group
Group type: COMPARATOR
Intervention: rhG-CSF
Number of subjects: 0
Study 26107532 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Integration Program (3 lessons per week for 6 weeks)
Number of subjects: 240
Study 26107532 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular mathematics program)
Number of subjects: 240
Study 24420155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total knee arthroplasty (TKA)
Number of subjects: 80
Study 24420155 — intervention group
Group type: COMPARATOR
Intervention: Cemented total knee arthroplasty (TKA)
Number of subjects: 80
Study 22569957 — intervention group
Group type: EXPERIMENTAL
Intervention: S/CRT (postoperative chemoradiation)
Number of subjects: 20
Study 22569957 — intervention group
Group type: COMPARATOR
Intervention: CRT (definitive chemoradiation)
Number of subjects: 20
Study 20142756 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biliary drainage (PBD)
Number of subjects: 24
Study 20142756 — intervention group
Group type: COMPARATOR
Intervention: Cholestatic patients (before PBD)
Number of subjects: 24
Study 20142756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestatic patients (after PBD)
Number of subjects: 24
Study 18783359 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17036555 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 64
Study 17036555 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethyltoluamide
Number of subjects: 64
Study 17036555 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin
Number of subjects: 64
Study 17036555 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 64
Study 17036555 — intervention group
Group type: COMPARATOR
Intervention: Physical and neurocognitive performance
Number of subjects: 64
Study 14740529 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power laser stimulation of acupuncture points for 10 days
Number of subjects: 50
Study 14740529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser stimulation)
Number of subjects: 50
Study 10756963 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of 15 micrograms/kg cisatracurium followed after 4 min by 85 micrograms/kg cisatracurium
Number of subjects: 51
Study 10756963 — intervention group
Group type: COMPARATOR
Intervention: Bolus of 100 micrograms/kg cisatracurium
Number of subjects: 51
Study 9082075 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptoreline depot (75 micrograms/kg/28 days/i.m.)
Number of subjects: 14
Study 9082075 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 untreated girls with advanced puberty and good predicted adult height)
Number of subjects: 14
Study 1610579 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrews spinal surgery frame
Number of subjects: 18
Study 1610579 — intervention group
Group type: COMPARATOR
Intervention: Cloward surgical saddle
Number of subjects: 18
Study 1610579 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal bolsters
Number of subjects: 18
Study 6092410 — intervention group
Group type: EXPERIMENTAL
Intervention: L5‐OH‐triptophan (20 mg iv)
Number of subjects: 18
Study 6092410 — intervention group
Group type: EXPERIMENTAL
Intervention: L5‐OH‐triptophan (40 mg iv)
Number of subjects: 18
Study 6092410 — intervention group
Group type: EXPERIMENTAL
Intervention: L5‐OH‐triptophan (200 mg orally)
Number of subjects: 18
Study 6092410 — intervention group
Group type: EXPERIMENTAL
Intervention: L5‐OH‐triptophan (400 mg orally)
Number of subjects: 18
Study 6092410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (15 mg orally)
Number of subjects: 18
Study 6092410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (30 mg orally)
Number of subjects: 18
Study 6092410 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide (3 X 2.8 mg orally)
Number of subjects: 18
Study 30281066 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS III-TT conjugate vaccine
Number of subjects: 650
Study 30281066 — intervention group
Group type: COMPARATOR
Intervention: Tetanus diphtheria toxoid vaccine
Number of subjects: 650
Study 29524199 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q SP
Number of subjects: 0
Study 29524199 — intervention group
Group type: COMPARATOR
Intervention: LMA Classic
Number of subjects: 0
Study 26174079 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group - two-step etch-and-rinse adhesive technique with oxalic acid pretreatment after acid-etched dentin
Number of subjects: 20
Study 26174079 — intervention group
Group type: COMPARATOR
Intervention: Control Group - two-step etch-and-rinse adhesive technique
Number of subjects: 20
Study 26174079 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study 24692847 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Number of subjects: 10
Study 24692847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22824435 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 3197
Study 22824435 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 3197
Study 20140343 — intervention group
Group type: EXPERIMENTAL
Intervention: Health interventions effective in Western industrialized settings
Number of subjects: 0
Study 18044192 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Plus Program
Number of subjects: 209
Study 16206346 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 2
Study 16206346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 16206346 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 2
Study 11815957 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC D‐99 (75 mg/m(2))
Number of subjects: 224
Study 11815957 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (75 mg/m(2))
Number of subjects: 224
Study 11815957 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC D‐99
Number of subjects: 224
Study 11815957 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 224
Study 9952144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3 ng/ml
Number of subjects: 226
Study 9952144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 6 ng/ml
Number of subjects: 226
Study 9952144 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/N2O group with increasing concentrations of fentanyl
Number of subjects: 226
Study 9952144 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane group with increasing concentrations of fentanyl
Number of subjects: 226
Study 7749156 — intervention group
Group type: COMPARATOR
Intervention: CAF (Cyclophosphamide, Adriamycin, and 5-Fluorouracil)
Number of subjects: 100
Study 7749156 — intervention group
Group type: EXPERIMENTAL
Intervention: CNF (Cyclophosphamide, Mitoxantrone, and 5-Fluorouracil)
Number of subjects: 100
Study 2248757 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol (1 mg once daily)
Number of subjects: 8
Study 2248757 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg once daily)
Number of subjects: 8
Study 7362725 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 80
Study 7362725 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 80
Study 31173341 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dose of 50-60 min of aerobic and resistance exercise (COMB)
Number of subjects: 301
Study 31336456 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency and Ultrasound (RF/US) combined with a low calorie diet, administered twice a week for 5 weeks
Number of subjects: 50
Study 31336456 — intervention group
Group type: COMPARATOR
Intervention: Low calorie diet only
Number of subjects: 50
Study 28225567 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepractice care
Number of subjects: 82
Study 28225567 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 82
Study 25662592 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab')₂ (0.85 U/kg body weight)
Number of subjects: 16
Study 25662592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16
Study 23582868 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to another SSRI or venlafaxine, with or without the addition of cognitive behavior therapy (CBT)
Number of subjects: 0